Kontush / Chapman High-Density Lipoproteins

Structure, Metabolism, Function and Therapeutics
1. Auflage 2011
ISBN: 978-1-118-15864-7
Verlag: John Wiley & Sons
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 648 Seiten, E-Book

A complete guide to the role of high-density lipoproteins (HDL)in new and emerging therapies
With high-density lipoproteins (HDL) playing an increasing rolein cardiovascular disease prevention, there is a growing need foran in-depth look at HDL and its clinical value. This booksummarizes the current state of knowledge in the field, providingfor the first time a comprehensive, systematic, stylisticallycoherent, and up-to-date review of the composition, structure,heterogeneity, metabolism, epidemiology, genetics, and function ofHDL.
Divided into three main parts, High-Density Lipoproteins firstexamines normal HDL particles, then describes defective HDL, andfinally addresses the therapeutic normalization of subnormal levelsand defective biological activities of this lipoprotein class. Thebook highlights the functional properties of HDL, which arerelevant to the pathophysiology of atherosclerosis and thrombosis,and discusses the compositional and metabolic heterogeneity of HDLparticles.
Readers will come away with a clear understanding of the role ofHDL in biological processes, the potential value of functional HDLas a therapeutic target, and how current and emerging therapies arepoised to influence the treatment of heart disease in thefuture.

Autoren/Hrsg.

Kontush, Anatol

Chapman, M. John

Inhaltsverzeichnis

Dedication.
Contents.
Abbreviations.
Preface.
Acknowledgements.
Section 1. Normal functional HDL.
Chapter 1.1 Composition.
Chapter 1.2 Heterogeneity.
Chapter 1.3 Structure.
1.4 Metabolism.
1.5 Epidemiology of HDL-C.
Chapter 1.6 Genetics.
Chapter 1.7 Biological activities.
Section 2. Functionally defective HDL.
Chapter 2.1 Altered composition.
Chapter 2.2 Abnormal metabolism.
Chapter 2.3 Impaired biological activities.
Section 3. Therapeutic normalization of subnormal levels and defective biological activities of HDL.
Chapter 3.1 Enhancement of HDL formation and normalization of intravascular HDL remodeling.
Chapter 3.2 Combination therapies.
Chapter 3.3 Other pharmacological approaches.
Chapter 3.4 Lifestyle modifications.
Conclusions and perspectives.

Über Autor(innen)

Anatol Kontush, BSc (Hons), PhD, is Research Director at theDyslipidemia and Atherosclerosis Research Unit of the NationalInstitute of Health and Medical Research (INSERM) at thePitié-Salpêtrière Hospital, Paris, France. Anaward-winning scientist, Dr. Kontush has authored more than 100original papers and book chapters.
M. John Chapman, BSc, PhD, DSc, FESC, is President of theEuropean Atherosclerosis Society and Director of the Dyslipidemiaand Atherosclerosis Research Unit of the National Institute ofHealth and Medical Research (INSERM) at thePitié-Salpêtrière Hospital in Paris, France,affiliated with the medical faculty of the Pierre and Marie CurieUniversity, Paris. He has authored more than 400 articles and bookchapters.